These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 16503144

  • 41. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
    Haesslein JL, Jullian N.
    Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
    [Abstract] [Full Text] [Related]

  • 42. Synthesis, biological activity, and SAR of antimycobacterial 2- and 8-substituted 6-(2-furyl)-9-(p-methoxybenzyl)purines.
    Braendvang M, Gundersen LL.
    Bioorg Med Chem; 2007 Nov 15; 15(22):7144-65. PubMed ID: 17804243
    [Abstract] [Full Text] [Related]

  • 43. Design and SAR of new substituted purines bearing aryl groups at N9 position as HIV-1 Tat-TAR interaction inhibitors.
    Pang R, Zhang C, Yuan D, Yang M.
    Bioorg Med Chem; 2008 Sep 01; 16(17):8178-86. PubMed ID: 18693018
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Synthesis of novel purine-based coxsackievirus inhibitors bearing polycylic substituents at the N-9 position.
    Dejmek M, Sála M, Plačková P, Hřebabecký H, Mascarell Borredà L, Neyts J, Dračínský M, Procházková E, Jansa P, Leyssen P, Mertlíková-Kaiserová H, Nencka R.
    Arch Pharm (Weinheim); 2014 Jul 01; 347(7):478-85. PubMed ID: 24652670
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
    Lipka DB, Kuck D, Kliem C, Gerhauser C.
    Expert Opin Ther Pat; 2013 Apr 01; 23(4):537-43. PubMed ID: 23448241
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 01; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Synthesis of 6,7,8-trisubstituted purines via a copper-catalyzed amidation reaction.
    Ibrahim N, Legraverend M.
    J Org Chem; 2009 Jan 02; 74(1):463-5. PubMed ID: 19012431
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD.
    J BUON; 2007 Sep 02; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. A solid-phase approach to novel purine and nucleoside analogs.
    Chang J, Dong C, Guo X, Hu W, Cheng S, Wang Q, Chen R.
    Bioorg Med Chem; 2005 Aug 01; 13(15):4760-6. PubMed ID: 15946848
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.